183 related articles for article (PubMed ID: 34864168)
1. Expanding horizons of achondroplasia treatment: current options and future developments.
Fafilek B; Bosakova M; Krejci P
Osteoarthritis Cartilage; 2022 Apr; 30(4):535-544. PubMed ID: 34864168
[TBL] [Abstract][Full Text] [Related]
2. FGFR3 targeting strategies for achondroplasia.
Laederich MB; Horton WA
Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
[TBL] [Abstract][Full Text] [Related]
3. Vosoritide: First Approval.
Duggan S
Drugs; 2021 Nov; 81(17):2057-2062. PubMed ID: 34694597
[TBL] [Abstract][Full Text] [Related]
4. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review.
Wrobel W; Pach E; Ben-Skowronek I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070375
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of vosoritide in the treatment of achondroplasia.
Paton DM
Drugs Today (Barc); 2022 Sep; 58(9):451-456. PubMed ID: 36102905
[TBL] [Abstract][Full Text] [Related]
6. Typical achondroplasia secondary to a unique insertional variant of FGFR3 with in vitro demonstration of its effect on FGFR3 function.
Meyer AN; Modaff P; Wang CG; Wohler E; Sobreira NL; Donoghue DJ; Pauli RM
Am J Med Genet A; 2021 Mar; 185(3):798-805. PubMed ID: 33368972
[TBL] [Abstract][Full Text] [Related]
7. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
Legeai-Mallet L
Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
[TBL] [Abstract][Full Text] [Related]
8. An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice.
Kimura T; Bosakova M; Nonaka Y; Hruba E; Yasuda K; Futakawa S; Kubota T; Fafilek B; Gregor T; Abraham SP; Gomolkova R; Belaskova S; Pesl M; Csukasi F; Duran I; Fujiwara M; Kavkova M; Zikmund T; Kaiser J; Buchtova M; Krakow D; Nakamura Y; Ozono K; Krejci P
Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952673
[TBL] [Abstract][Full Text] [Related]
9. Effect of the G375C and G346E achondroplasia mutations on FGFR3 activation.
He L; Serrano C; Niphadkar N; Shobnam N; Hristova K
PLoS One; 2012; 7(4):e34808. PubMed ID: 22529939
[TBL] [Abstract][Full Text] [Related]
10. Achondroplasia: Development, pathogenesis, and therapy.
Ornitz DM; Legeai-Mallet L
Dev Dyn; 2017 Apr; 246(4):291-309. PubMed ID: 27987249
[TBL] [Abstract][Full Text] [Related]
11. Physical basis behind achondroplasia, the most common form of human dwarfism.
He L; Horton W; Hristova K
J Biol Chem; 2010 Sep; 285(39):30103-14. PubMed ID: 20624921
[TBL] [Abstract][Full Text] [Related]
12. Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.
Sarabipour S; Hristova K
Biochim Biophys Acta; 2016 Jul; 1858(7 Pt A):1436-42. PubMed ID: 27040652
[TBL] [Abstract][Full Text] [Related]
13. Achondroplasia: pathogenesis and implications for future treatment.
Laederich MB; Horton WA
Curr Opin Pediatr; 2010 Aug; 22(4):516-23. PubMed ID: 20601886
[TBL] [Abstract][Full Text] [Related]
14. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
Foldynova-Trantirkova S; Wilcox WR; Krejci P
Hum Mutat; 2012 Jan; 33(1):29-41. PubMed ID: 22045636
[TBL] [Abstract][Full Text] [Related]
15. Achondroplasia.
Horton WA; Hall JG; Hecht JT
Lancet; 2007 Jul; 370(9582):162-172. PubMed ID: 17630040
[TBL] [Abstract][Full Text] [Related]
16. FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.
He L; Shobnam N; Wimley WC; Hristova K
J Biol Chem; 2011 Apr; 286(15):13272-81. PubMed ID: 21324899
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.
Gonçalves D; Rignol G; Dellugat P; Hartmann G; Sarrazy Garcia S; Stavenhagen J; Santarelli L; Gouze E; Czech C
PLoS One; 2020; 15(12):e0244368. PubMed ID: 33370388
[TBL] [Abstract][Full Text] [Related]
19. Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family.
Ajmal M; Mir A; Shoaib M; Malik SA; Nasir M
Diagn Pathol; 2017 Jul; 12(1):47. PubMed ID: 28679403
[TBL] [Abstract][Full Text] [Related]
20. A registry of achondroplasia: a 6-year experience from the Czechia and Slovak Republic.
Pesl M; Verescakova H; Skutkova L; Strenkova J; Krejci P
Orphanet J Rare Dis; 2022 Jun; 17(1):229. PubMed ID: 35710503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
